RGBP (Regen BioPharma) Short-Term Debt: $0.96 Mil (As of Mar. 2026)


What is Regen BioPharma Short-Term Debt?

Regen BioPharma RGBP Short-Term Debt is $0.96 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Regen BioPharma's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.96 Mil.

Regen BioPharma's quarterly Short-Term Debt declined from Sep. 2025 ($1.20 Mil) to Dec. 2025 ($1.08 Mil) and declined from Dec. 2025 ($1.08 Mil) to Mar. 2026 ($0.96 Mil).

Regen BioPharma's annual Short-Term Debt increased from Sep. 2023 ($0.61 Mil) to Sep. 2024 ($0.79 Mil) and increased from Sep. 2024 ($0.79 Mil) to Sep. 2025 ($1.20 Mil).

Regen BioPharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Regen BioPharma Short-Term Debt Related Terms

Regen BioPharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Short-Term Debt Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.58 1.27 0.61 0.79 1.20

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.04 1.20 1.08 0.96
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.96 Mil mean?
Regen BioPharma (RGBP) has a Short-Term Debt of $0.96 Mil as of Mar. 2026.
Is Regen BioPharma's Short-Term Debt too high?
Regen BioPharma's current Short-Term Debt is $0.96 Mil.
How does Regen BioPharma's Short-Term Debt compare to SIGY and ENDV?
Regen BioPharma's Short-Term Debt of $0.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Regen BioPharma's current Short-Term Debt is $0.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current Short-Term Debt is $0.96 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Short-Term Debt is $0.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.